Erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of VTE and mortality.
References and Resources
Bennett C., Silver S., Djulbegovic B., et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia 2008. JAMA. 299(8):914-924.
Sponsored by The Doctor’s Channel